RENEWED PETITION UNDER 37 CFR 1.137(b)				Docket Number (Optional) 10546-109
First Named inventor: Micha	ael J. Borrelli, Ph.D.		Art Unit:	1635
Application Number: 10/76	<u>4,316</u>	Examiner:	Chong, Kimberl	¥
Filed: January 23, 2004				
Title: METHODS AND COM	MPOSITIONS FOR HEAT ACTIVATED GENE	THERAPY US	SING CYTOLETHA	AL DISTENDING TOXIN
Attention: Office of Petitions Mail Stop Petition Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 FAX (571) 273-8300				
NOTE: If information or assistance is needed in completing this form, please contact				
	Petitions Information at (571)	272-3282.		
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.				
NOTE: A (1) Petitic (2) Reply (3) Termi and fo	IT HEREBY PETITIONS FOR REVIVAL OF TH grantable petition requires the following items: in fee. and/or issue fee. and disclaimer with disclaimer fee-required for a r all design applications; and ment that the entire delay was unintentional.			ed before June 8, 1995,
Other than sma 2. Reply and/or fee: A. The reply and/or has be	\$770.00 (37 CFR 1.17(m)). Applicant claims s il entity – fee \$(37 CFR 1.17(i)). If fee to the above-noted Office action in the form en filed previously filed on Seed herewith.			
B. The issue fee of ☐ has be	\$en filed previously filed on			

is enclosed herewith.

	_			
RENEWED PETITION UNDER 37 CFR 1.137(b)				
3. Terminal disclaimer with disclaimer fee				
☑ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.				
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).				
4. STATEMENT: The entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional informs there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was uninten (MPEP 711.03(c), subsections (III)(C) and (D)).]				
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication from the application is available to the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR.1.14). Cast a suthorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.				
/Eric J. Baude/ August 25, 2008 Signature Date				
Eric J. Baude Typed or Printed Name Registration No., if applicable				
Brinks Hofer Gilson & Lione				
Attachment(s) Reply Terminal Disclaimer Form Additional sheets containing statements establishing unavoidable delay Other: RCE; AMENDMENT AFTER FINAL (5 page).				
CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8 I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:				
Date: August 25, 2008 Name: Eric J. Baude Signature: /EJB/				